Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 4Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Thrombocytopenia 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1

Interventions

Cyclophosphamide 678Cytarabine 576fludarabine 410fludarabine phosphate 387venetoclax 310Methotrexate 297Rituximab 283Azacitidine 264Busulfan 248Whole-Body Irradiation 220Etoposide 215Filgrastim 214Peripheral Blood Stem Cell Transplantation 211Mycophenolic Acid 206Tacrolimus 196Dexamethasone 191Granulocyte Colony-Stimulating Factor 182Vincristine 173Melphalan 173Decitabine 163Cyclosporine 146Daunorubicin 139Antilymphocyte Serum 137Idarubicin 134Imatinib Mesylate 127Lenalidomide 116Doxorubicin 109Radiotherapy 108Stem Cell Transplantation 107Clofarabine 106

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × oprelvekin × Other hematologic neoplasm × Clear all
NCT00493181 2012-02-20

Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients

M.D. Anderson Cancer Center

Phase 2 Completed
8 enrolled 3 charts
Classical hematologyMyeloidOther hematologic neoplasm

Leukemia, Thrombocytopenia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡